ALHC Alignment Healthcare, Inc. Insider Trading

Mark D. Kent (President - MSO) purchases 14,848 shares of ALHC at $13.31 as stock down 42.9% from 52-week high.

Mark D. Kent, President of Alignment Healthcare's MSO division, initiated a new position of 14,848 shares at $13.31 on 2026-06-02, purchasing approximately $197,626.88 in stock. This entry comes during a period of significant price weakness: the stock is trading 42.9% below its 52-week high of $23.87, down 32.7% over the prior 30 days and 27.8% over 90 days. Notably, the company is trading at a P/E of 136.40 despite reporting full-year net income that was negative, indicating the equity currently prices in future profitability improvements. The concurrent strength in fundamentals (annual revenue growth of +46.1%, latest-quarter revenue of $1,235,197,000.00) provides context for the purchase timing relative to stock-price depreciation.

ALHC CEO John Kao sells roughly 298k shares in two tranches; stock trading well below 52-week highs amid unprofitable fundamentals.

CEO John Kao disposed of approximately 298,000 shares across two transactions, reducing his stake by a combined sixteen percent—a material liquidation for a top executive. This sale is the sixth and seventh of Kao's open-market exits at ALHC over the past three years, underscoring a consistent seller posture. The company remains unprofitable despite strong revenue growth, and the stock is trading well below its 52-week high while down over the past month, creating an unfavorable backdrop for executive selling. What stands out is Kao's execution track record: his five prior sales at ALHC were all well-timed at both the 30-day and 90-day horizons—in each case the stock declined after he sold—suggesting he has successfully identified weak periods to exit. Placing these two additional sales in that consistent pattern raises a question about whether near-term price weakness signals operational headwinds the market has not yet fully priced in.